<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31999342</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients.</ArticleTitle><Pagination><StartPage>266</StartPage><EndPage>276</EndPage><MedlinePgn>266-276</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnen/nlz142</ELocationID><Abstract><AbstractText>For amyotrophic lateral sclerosis (ALS), achieving and maintaining effective drug levels in the brain is challenging due to the activity of ATP-binding cassette (ABC) transporters which efflux drugs that affect drug exposure and response in the brain. We investigated the expression and cellular distribution of the ABC transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) using immunohistochemistry in spinal cord (SC), motor cortex, and cerebellum from a large cohort of genetically well characterized ALS patients (n&#x2009;=&#x2009;25) and controls (n&#x2009;=&#x2009;14). The ALS group included 17 sporadic (sALS) and 8 familial (fALS) patients. Strong P-gp expression was observed in endothelial cells in both control and ALS specimens. Immunohistochemical analysis showed higher P-gp expression in reactive astroglial cells in both gray (ventral horn) and white matter of the SC, as well as in the motor cortex of all ALS patients, as compared with controls. BCRP expression was higher in glia in the SC and in blood vessels and glia in the motor cortex of ALS patients, as compared with controls. P-gp and BCRP immunoreactivity did not differ between sALS and fALS cases. The upregulation of both ABC transporters in the brain may explain multidrug resistance in ALS patients and has implications for the use of both approved and experimental therapeutics.</AbstractText><CopyrightInformation>&#xa9; 2019 American Association of Neuropathologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Vliet</LastName><ForeName>Erwin A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>From the Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Anand M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From the Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesarosova</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc7;olakoglu</LastName><ForeName>Hilal</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Pharmacology, The Netherlands Cancer Institute (H&#xc7;, OvT), Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anink</LastName><ForeName>Jasper J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>From the Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Tellingen</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Pharmacology, The Netherlands Cancer Institute (H&#xc7;, OvT), Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maragakis</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunt</LastName><ForeName>Ton</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Izumi Biosciences, Inc., Lexington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronica</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C116614">ABCG2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020168">ATP Binding Cassette Transporter, Subfamily B, Member 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070997">ATP Binding Cassette Transporter, Subfamily G, Member 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020168" MajorTopicYN="N">ATP Binding Cassette Transporter, Subfamily B, Member 1</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070997" MajorTopicYN="N">ATP Binding Cassette Transporter, Subfamily G, Member 2</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Astrocytes</Keyword><Keyword MajorTopicYN="N">BCRP</Keyword><Keyword MajorTopicYN="N">Blood vessels</Keyword><Keyword MajorTopicYN="N">Motor cortex</Keyword><Keyword MajorTopicYN="N">Multidrug resistance</Keyword><Keyword MajorTopicYN="N">P-glycoprotein (P-gp)</Keyword><Keyword MajorTopicYN="N">Spinal cord</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31999342</ArticleId><ArticleId IdType="pmc">PMC7036662</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlz142</ArticleId><ArticleId IdType="pii">5718003</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, et al. Neuropathology of amyotrophic lateral sclerosis and its variants. Neurol Clin 2015;33:855&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ. Revisiting the concept of amyotrophic lateral sclerosis as a multisystems disorder of limited phenotypic expression. Curr Opin Neurol 2017;30:599&#x2013;607</Citation><ArticleIdList><ArticleId IdType="pubmed">28914734</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris HR, Waite AJ, Williams NM, et al. Recent advances in the genetics of the ALS-FTLD complex. Curr Neurol Neurosci Rep 2012;12:243&#x2013;50</Citation><ArticleIdList><ArticleId IdType="pubmed">22477152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Sias AC, Mandelli ML, et al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin 2017;14:286&#x2013;97</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J.. Gene discovery in amyotrophic lateral sclerosis: Implications for clinical management. Nat Rev Neurol 2017;13:96&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJ, Koppers M, et al. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 2013;125:777&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Edens BM, Miller N, Ma YC.. Impaired autophagy and defective mitochondrial function: Converging paths on the road to motor neuron degeneration. Front Cell Neurosci 2016;10:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4776126</ArticleId><ArticleId IdType="pubmed">26973461</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Gonzalo I, Ruiz-Soto M, et al. Why do motor neurons degenerate? Actualization in the pathogenesis of amyotrophic lateral sclerosis. Neurologia 2019;34:27&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">26853842</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH. Amyotrophic lateral sclerosis: Pathophysiology, diagnosis and management. CNS Drugs 2011;25:1&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pubmed">21128691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Ryu H, Keum G, et al. Therapeutic targeting of epigenetic components in amyotrophic lateral sclerosis (ALS). CMC 2014;21:3576&#x2013;82</Citation><ArticleIdList><ArticleId IdType="pubmed">25005187</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, Jacob DA, Campos C, et al. Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis 2012;47:194&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367047</ArticleId><ArticleId IdType="pubmed">22521463</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski M, Miller DS, Pasinelli P, et al. ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis. Brain Res 2015;1607:1&#x2013;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344920</ArticleId><ArticleId IdType="pubmed">25175835</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed LA, Markandaiah S, Bonanno S, et al. Blood-brain barrier driven pharmacoresistance in amyotrophic lateral sclerosis and challenges for effective drug therapies. AAPS J 2017;19:1600&#x2013;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6571115</ArticleId><ArticleId IdType="pubmed">28779378</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Sanberg PR.. Blood-CNS Barrier Impairment in ALS patients versus an animal model. Front Cell Neurosci 2014;8:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003;55:425&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">12869659</ArticleId></ArticleIdList></Reference><Reference><Citation>Loscher W, Potschka H.. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Neurotherapeutics 2005;2:86&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539326</ArticleId><ArticleId IdType="pubmed">15717060</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica E, Sisodiya SM, Gorter JA.. Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev 2012;64:919&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pubmed">22138133</ArticleId></ArticleIdList></Reference><Reference><Citation>Boston-Howes W, Williams EO, Bogush A, et al. Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: Therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol 2008;213:229&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600491</ArticleId><ArticleId IdType="pubmed">18625223</ArticleId></ArticleIdList></Reference><Reference><Citation>Milane A, Fernandez C, Dupuis L, et al. P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci Lett 2010;472:166&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pubmed">20138122</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, Markandaiah SS, Jacob D, et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann Clin Transl Neurol 2014;1:996&#x2013;1005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284125</ArticleId><ArticleId IdType="pubmed">25574474</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H, Miller DS, Pasinelli P, et al. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res 2015;1628:298&#x2013;316</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4681613</ArticleId><ArticleId IdType="pubmed">26187753</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H, Lichter J, Sarlo M, et al. Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. Glia 2016;64:1298&#x2013;313</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541958</ArticleId><ArticleId IdType="pubmed">27158936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan GN, Evans RA, Banks DB, et al. Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model. Neurosci Lett 2017;639:103&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278641</ArticleId><ArticleId IdType="pubmed">28011392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria &#x2013; 2015. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:291&#x2013;2</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula M, Iyer AM, Spliet WG, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011;179:233&#x2013;43</Citation><ArticleIdList><ArticleId IdType="pubmed">21303685</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Loos CM. Multiple immunoenzyme staining: Methods and visualizations for the observation with spectral imaging. J Histochem Cytochem 2008;56:313&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2326109</ArticleId><ArticleId IdType="pubmed">18158282</ArticleId></ArticleIdList></Reference><Reference><Citation>Boer K, Troost D, Timmermans W, et al. Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Neuroscience 2008;156:203&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pubmed">18706978</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott NJ, Ronnback L, Hansson E.. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pubmed">16371949</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeier B, Daneman R, Ransohoff RM.. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19:1584&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4080800</ArticleId><ArticleId IdType="pubmed">24309662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijaya J, Fukuda Y, Schuetz JD.. Obstacles to brain tumor therapy: Key ABC transporters. Int J Mol Sci 2017;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5751147</ArticleId><ArticleId IdType="pubmed">29186899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowski SA, Fredriksson L, Lawrence DA, et al. Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders. Pharmacol Ther 2016;167:108&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5341142</ArticleId><ArticleId IdType="pubmed">27524729</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanimirovic DB, Friedman A.. Pathophysiology of the neurovascular unit: Disease cause or consequence? J Cereb Blood Flow Metab 2012;32:1207&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390807</ArticleId><ArticleId IdType="pubmed">22395208</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178&#x2013;201</Citation><ArticleIdList><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels AL, Willemsen AT, Kortekaas R, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm) 2008;115:1001&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2468317</ArticleId><ArticleId IdType="pubmed">18265929</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford D, Grigorian A, Hurford R, et al. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004;63:1038&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">15535131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooij G, Mizee MR, van Horssen J, et al. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: Relevance to multiple sclerosis pathogenesis. Brain 2011;134:555&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pubmed">21183485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2009;106:18809&#x2013;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">16518375</ArticleId></ArticleIdList></Reference><Reference><Citation>Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18:452&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622180</ArticleId><ArticleId IdType="pubmed">29643473</ArticleId></ArticleIdList></Reference><Reference><Citation>Neul C, Schaeffeler E, Sparreboom A, et al. Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors. Trends Pharmacol Sci 2016;37:904&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pubmed">27659854</ArticleId></ArticleIdList></Reference><Reference><Citation>Loscher W, Potschka H.. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591&#x2013;602</Citation><ArticleIdList><ArticleId IdType="pubmed">16025095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T, Islam O, Heese K.. ABC transporters, neural stem cells and neurogenesis&#x2014;A different perspective. Cell Res 2006;16:857&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pubmed">17088897</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J, Haefeli WE.. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol 2010;280:219&#x2013;79</Citation><ArticleIdList><ArticleId IdType="pubmed">20797684</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyal S, Hsiao P, Unadkat JD.. Drug interactions at the blood-brain barrier: Fact or fantasy? Pharmacol Ther 2009;123:80&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751796</ArticleId><ArticleId IdType="pubmed">19393264</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Hartz AM, Elmquist WF, et al. Breast cancer resistance protein and P-glycoprotein in brain cancer: Two gatekeepers team up. CPD 2011;17:2793&#x2013;802</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269897</ArticleId><ArticleId IdType="pubmed">21827403</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508566</ArticleId><ArticleId IdType="pubmed">9435299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharm 2004;7:415&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">15683552</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries NA, Buckle T, Zhao J, et al. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2012;30:443&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">20963470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, et al. Riluzole and amyotrophic lateral sclerosis survival: A population-based study in southern Italy. Eur J Neurol 2007;14:262&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">17355545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V.. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585&#x2013;91</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, et al. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci 2017;9:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12:54&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">17198973</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitchcock SA. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr Opin Chem Biol 2008;12:318&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pubmed">18435937</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss N, Miller F, Cazaubon S, et al. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009;1788:842&#x2013;57</Citation><ArticleIdList><ArticleId IdType="pubmed">19061857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecuyer MA, Kebir H, Prat A.. Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta 2016;1862:472&#x2013;82</Citation><ArticleIdList><ArticleId IdType="pubmed">26454208</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooij G, Backer R, Koning JJ, et al. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One 2009;4:e8212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785479</ArticleId><ArticleId IdType="pubmed">19997559</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed LA, Markandaiah SS, Bonanno S, et al. Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis. Exp Neurol 2019;316:27&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506236</ArticleId><ArticleId IdType="pubmed">30974102</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcagno AM, Kim IW, Wu CP, et al. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. CDD 2007;4:324&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">17979652</ArticleId></ArticleIdList></Reference><Reference><Citation>Milane A, Vautier S, Chacun H, et al. Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett 2009;452:12&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">19146924</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulin JN, Moore ML, Grill RJ.. The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord. J Neurotrauma 2013;30:211&#x2013;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3565554</ArticleId><ArticleId IdType="pubmed">22947335</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh A, Kathawala K, Tan CC, et al. Self-nanomicellizing solid dispersion of edaravone: Part I &#x2013; Oral bioavailability improvement. DDDT 2018;12:2051&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6038876</ArticleId><ArticleId IdType="pubmed">30013324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocic I, Kowianski P, Rusiecka I, et al. Neuroprotective effect of masitinib in rats with postischemic stroke. Naunyn-Schmiedeberg's Arch Pharmacol 2015;388:79&#x2013;86</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284372</ArticleId><ArticleId IdType="pubmed">25344204</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698&#x2013;705</Citation><ArticleIdList><ArticleId IdType="pmc">PMC185805</ArticleId><ArticleId IdType="pubmed">7560060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkinezos IG, Hernandez D, Bradley WG, et al. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J Neurochem 2004;88:821&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">14756802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y, Takahara S, Kato S, et al. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos 2008;36:1088&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pubmed">18339814</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman M, Selvarajan K, Hasan MR, et al. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia 2012;14:624&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421958</ArticleId><ArticleId IdType="pubmed">22904679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XQ, Zhang HM, Sun XE, et al. Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice. Exp Ther Med 2015;9:105&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4247324</ArticleId><ArticleId IdType="pubmed">25452783</ArticleId></ArticleIdList></Reference><Reference><Citation>Vautier S, Milane A, Fernandez C, et al. Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model. Neurosci Lett 2008;442:19&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pubmed">18598736</ArticleId></ArticleIdList></Reference><Reference><Citation>West CL, Mealey KL.. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. Am J Vet Res 2007;68:1106&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pubmed">17916018</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi H, Yonezawa A, Matsubara K, et al. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models. Eur J Pharmacol 2013;710:20&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">23588114</ArticleId></ArticleIdList></Reference><Reference><Citation>Monville C, Fages C, Feyens AM, et al. Astroglial expression of the P-glycoprotein is controlled by intracellular CNTF. BMC Cell Biol 2002;3:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117802</ArticleId><ArticleId IdType="pubmed">12150717</ArticleId></ArticleIdList></Reference><Reference><Citation>Sills GJ, Kwan P, Butler E, et al. P-glycoprotein-mediated efflux of antiepileptic drugs: Preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002;3:427&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pubmed">12609264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustacich DJ, Vo AT, Elias VD, et al. Regulatory mechanisms to control tissue alpha-tocopherol. Free Radic Biol Med 2007;43:610&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693716</ArticleId><ArticleId IdType="pubmed">17640571</ArticleId></ArticleIdList></Reference><Reference><Citation>Traber MG, Labut EM, Leonard SW, et al. alpha-Tocopherol injections in rats up-regulate hepatic ABC transporters, but not cytochrome P450 enzymes. Free Radic Biol Med 2011;51:2031&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208783</ArticleId><ArticleId IdType="pubmed">21945367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kis O, Robillard K, Chan GN, et al. The complexities of antiretroviral drug-drug interactions: Role of ABC and SLC transporters. Trends Pharmacol Sci 2010;31:22&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">20004485</ArticleId></ArticleIdList></Reference><Reference><Citation>Oostendorp RL, Buckle T, Beijnen JH, et al. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 2009;27:31&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">18449471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>